US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Aardvark Therapeutics

12.65

+1.3612.05%

Post-market: 12.650.00000.00%17:43 EST

Volume:152.07K

Turnover:1.90M

Market Cap:274.47M

PE:-5.64

High:13.03

Open:11.61

Low:11.51

Close:11.29

52wk High:19.58

52wk Low:4.88

Shares:21.70M

Float Shares:5.89M

Volume Ratio:0.92

T/O Rate:2.58%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.2430

EPS(LYR):-0.7400

ROE:-48.06%

ROA:-30.81%

PB:2.24

PE(LYR):-17.09

Loading ...

Overview Company News Filings

B. Riley Initiates Aardvark Therapeutics at Buy With $32 Price Target

MT Newswires Live

Aardvark Therapeutics Inc : B. Riley Initiates Coverage With Buy Rating; Target Price $32

THOMSON REUTERS

Aardvark Therapeutics initiated with a Buy at B. Riley

Ten new option listings and two option delistings on January 22nd

Aardvark Therapeutics: Clinical Momentum and 2026 Catalyst Stack Underpin Buy Rating and $26 Target

Aardvark Therapeutics Inc : Oppenheimer Initiates Coverage With Outperform Rating; Target Price $35

THOMSON REUTERS

BUZZ-Oppenheimer starts Aardvark with 'outperform' on differentiated obesity franchise

Aardvark Therapeutics CEO Tien-Li Lee Reports Acquisition of Common Shares

Aardvark's Hunger Suppressing Drug Candidate Could Potentially Address Massive $10 Billion Market: Analyst

Benzinga_recent_news

Aardvark Therapeutics Initiated at Outperform by William Blair

William Blair Initiates Aardvark Therapeutics With Outperform Rating

MT Newswires Live

Aardvark Therapeutics Doses First Patient in Phase 3 HERO Trial for Prader-Willi Syndrome

Aardvark Therapeutics Announces First Patient Dosed in Australia in Hero Phase 3 Trial for Prader-Willi Syndrome

THOMSON REUTERS

Aardvark Therapeutics Inc - Regulatory Clearance for Enrollment by Clinical Trial Sites in Canada and the UK Has Also Been Received

THOMSON REUTERS

Raymond James Initiates Aardvark Therapeutics at Strong Buy

MT Newswires Live

Aardvark Therapeutics to Present at Upcoming Healthcare Investor Conferences

Aardvark Therapeutics Reports Q3 2025 Financial Results

Aardvark Therapeutics Is Maintained at Outperform by RBC Capital

Cantor Fitzgerald Reaffirms Their Buy Rating on Aardvark Therapeutics, Inc. (AARD)

BTIG Remains a Buy on Aardvark Therapeutics, Inc. (AARD)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/AARD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AARD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AARD\",,,,,undefined,":{"symbol":"AARD","market":"US","secType":"STK","nameCN":"Aardvark Therapeutics","latestPrice":12.65,"timestamp":1770411600000,"preClose":11.29,"halted":0,"volume":152066,"hourTrading":{"tag":"盘后","latestPrice":12.65,"preClose":12.65,"latestTime":"17:43 EST","volume":566,"amount":7135.74,"timestamp":1770417822261,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.1204605845881312,"floatShares":5888000,"shares":21696893,"eps":-2.243,"marketStatus":"Market Closed","change":1.36,"latestTime":"02-06 16:00:00 EST","open":11.61,"high":13.03,"low":11.51,"amount":1897008.5995979998,"amplitude":0.134632,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.243,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"listingDate":1739509200000,"exchange":"NASDAQ","adjPreClose":11.29,"preHourTrading":{"tag":"盘前","latestPrice":11.351,"preClose":11.29,"latestTime":"09:22 EST","volume":59,"amount":694.354008,"timestamp":1770387738746,"change":0.061,"changeRate":0.005403,"amplitude":0.083171},"postHourTrading":{"tag":"盘后","latestPrice":12.65,"preClose":12.65,"latestTime":"17:43 EST","volume":566,"amount":7135.74,"timestamp":1770417822261,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.918058,"impliedVol":0.8098,"impliedVolPercentile":0.4167},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AARD\",,,,,undefined,":{"symbol":"AARD","floatShares":5888000,"roa":"-30.81%","roe":"-48.06%","lyrEps":-0.74,"volumeRatio":0.918058,"shares":21696893,"dividePrice":0,"high":13.03,"amplitude":0.134632,"preClose":11.29,"low":11.51,"week52Low":4.88,"pbRate":"2.24","week52High":19.58,"institutionHeld":0,"latestPrice":12.65,"eps":-2.243,"divideRate":0,"volume":152066,"delay":0,"ttmEps":-2.243,"open":11.61,"prevYearClose":13.125,"prevWeekClose":12.99,"prevMonthClose":12.99,"prevQuarterClose":13.125},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AARD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-13","symbol":"AARD","fiscalQuarterEnding":"2025/09","expectedEps":-0.82,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.75},{"market":"US","date":"2025-08-13","symbol":"AARD","fiscalQuarterEnding":"2025/06","expectedEps":-0.52,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-0.66},{"market":"US","date":"2025-05-14","symbol":"AARD","fiscalQuarterEnding":"2025/03","expectedEps":-0.7,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-0.71},{"market":"US","date":"2025-03-31","symbol":"AARD","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AARD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AARD\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AARD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AARD","date":"2026-02-05","current":-5.639768,"percent":0.888889,"low":-51.17654,"twenty":-10.796303,"median":-8.045838,"eighty":-6.041207,"high":-4.13394,"avg":-10.933093,"sd":9.011314,"marketCap":273472296},"quantilePoints":[{"date":"2025-02-21","current":-51.17654,"twenty":-46.993414,"median":-42.216938,"eighty":-39.920668,"marketCap":368880503},{"date":"2025-02-28","current":-39.75453,"twenty":-42.139802,"median":-40.229211,"eighty":-39.232381,"marketCap":286550651},{"date":"2025-03-07","current":-28.243517,"twenty":-40.603022,"median":-39.176012,"eighty":-36.900511,"marketCap":203579269},{"date":"2025-03-14","current":-31.091602,"twenty":-40.336014,"median":-37.766803,"eighty":-30.723725,"marketCap":224108270},{"date":"2025-03-21","current":-27.23482,"twenty":-39.944402,"median":-34.681377,"eighty":-29.198812,"marketCap":196308580},{"date":"2025-03-28","current":-26.404128,"twenty":-39.576524,"median":-30.913597,"eighty":-27.946841,"marketCap":190320955},{"date":"2025-04-04","current":-9.026143,"twenty":-39.119644,"median":-30.068072,"eighty":-27.341623,"marketCap":185830236},{"date":"2025-04-11","current":-7.397773,"twenty":-38.751766,"median":-29.400552,"eighty":-17.252871,"marketCap":152305358},{"date":"2025-04-17","current":-7.977371,"twenty":-38.300819,"median":-28.45119,"eighty":-8.603741,"marketCap":164238114},{"date":"2025-04-25","current":-8.66235,"twenty":-37.766803,"median":-27.946841,"eighty":-8.371497,"marketCap":178340462},{"date":"2025-05-02","current":-11.939711,"twenty":-36.900511,"median":-27.412825,"eighty":-8.371497,"marketCap":245814773},{"date":"2025-05-09","current":-11.307423,"twenty":-34.865316,"median":-26.68597,"eighty":-8.46634,"marketCap":232797221},{"date":"2025-05-16","current":-7.114571,"twenty":-32.693651,"median":-13.552046,"eighty":-8.46634,"marketCap":197215912},{"date":"2025-05-23","current":-7.834638,"twenty":-31.0204,"median":-11.823792,"eighty":-8.360959,"marketCap":217176159},{"date":"2025-05-30","current":-8.061615,"twenty":-30.818661,"median":-11.433881,"eighty":-8.172533,"marketCap":223467976},{"date":"2025-06-06","current":-9.353039,"twenty":-30.367714,"median":-11.107198,"eighty":-8.178795,"marketCap":259266244},{"date":"2025-06-13","current":-8.656453,"twenty":-30.076972,"median":-10.833207,"eighty":-8.210998,"marketCap":239956875},{"date":"2025-06-20","current":-9.454788,"twenty":-30.053238,"median":-10.188135,"eighty":-8.218152,"marketCap":262086713},{"date":"2025-06-27","current":-10.84796,"twenty":-29.697227,"median":-10.664596,"eighty":-8.356744,"marketCap":300705451},{"date":"2025-07-03","current":-10.894921,"twenty":-29.459887,"median":-10.613156,"eighty":-8.365174,"marketCap":302007206},{"date":"2025-07-11","current":-9.861782,"twenty":-29.308323,"median":-10.597502,"eighty":-8.375712,"marketCap":273368592},{"date":"2025-07-18","current":-9.360866,"twenty":-28.618005,"median":-10.433139,"eighty":-8.40036,"marketCap":259483203},{"date":"2025-07-25","current":-10.542714,"twenty":-28.285052,"median":-10.45662,"eighty":-8.474871,"marketCap":292244042},{"date":"2025-08-01","current":-9.4,"twenty":-28.006176,"median":-10.433139,"eighty":-8.577715,"marketCap":260567999},{"date":"2025-08-08","current":-9.368693,"twenty":-27.946841,"median":-10.061366,"eighty":-8.607418,"marketCap":259700162},{"date":"2025-08-15","current":-6.668132,"twenty":-27.567096,"median":-9.861782,"eighty":-8.474871,"marketCap":244307015},{"date":"2025-08-22","current":-5.762071,"twenty":-27.424692,"median":-9.803081,"eighty":-8.329026,"marketCap":211110768},{"date":"2025-08-29","current":-5.027748,"twenty":-27.270421,"median":-9.525229,"eighty":-8.145134,"marketCap":184206621},{"date":"2025-09-05","current":-5.027748,"twenty":-27.074615,"median":-9.478268,"eighty":-8.014507,"marketCap":184206621},{"date":"2025-09-12","current":-4.61321,"twenty":-26.629602,"median":-9.396086,"eighty":-7.797069,"marketCap":169018796},{"date":"2025-09-19","current":-6.685898,"twenty":-23.929853,"median":-9.368693,"eighty":-7.515801,"marketCap":244957921},{"date":"2025-09-26","current":-7.503129,"twenty":-17.043362,"median":-9.298251,"eighty":-7.308831,"marketCap":274899634},{"date":"2025-10-03","current":-9.102059,"twenty":-12.821851,"median":-9.210333,"eighty":-7.389343,"marketCap":333481245},{"date":"2025-10-10","current":-9.824539,"twenty":-12.161077,"median":-9.298251,"eighty":-7.460987,"marketCap":359951454},{"date":"2025-10-17","current":-7.876213,"twenty":-12.040618,"median":-9.212156,"eighty":-7.503145,"marketCap":288568676},{"date":"2025-10-24","current":-6.425331,"twenty":-11.978881,"median":-9.149542,"eighty":-7.334887,"marketCap":235411289},{"date":"2025-10-31","current":-6.194375,"twenty":-11.800608,"median":-9.102059,"eighty":-7.096882,"marketCap":226949500},{"date":"2025-11-07","current":-5.844979,"twenty":-11.619352,"median":-9.083015,"eighty":-6.739195,"marketCap":214148333},{"date":"2025-11-14","current":-6.453893,"twenty":-11.527382,"median":-8.978494,"eighty":-6.599437,"marketCap":236457733},{"date":"2025-11-21","current":-4.209833,"twenty":-11.386619,"median":-8.807467,"eighty":-6.451943,"marketCap":205321954},{"date":"2025-11-28","current":-4.455369,"twenty":-11.26527,"median":-8.719067,"eighty":-6.366112,"marketCap":217297254},{"date":"2025-12-05","current":-5.535729,"twenty":-11.176245,"median":-8.71121,"eighty":-6.20385,"marketCap":269988572},{"date":"2025-12-12","current":-6.968768,"twenty":-11.12541,"median":-8.663092,"eighty":-6.182531,"marketCap":339880775},{"date":"2025-12-19","current":-6.111623,"twenty":-11.06083,"median":-8.610671,"eighty":-6.174808,"marketCap":298076093},{"date":"2025-12-26","current":-6.366088,"twenty":-10.989171,"median":-8.599121,"eighty":-6.172233,"marketCap":310486858},{"date":"2026-01-02","current":-5.859391,"twenty":-10.980741,"median":-8.405995,"eighty":-6.111623,"marketCap":285774195},{"date":"2026-01-09","current":-6.477696,"twenty":-10.894921,"median":-8.362013,"eighty":-6.093766,"marketCap":315930176},{"date":"2026-01-16","current":-6.852697,"twenty":-10.894921,"median":-8.218152,"eighty":-6.111623,"marketCap":334219725},{"date":"2026-01-23","current":-6.732161,"twenty":-10.894921,"median":-8.171191,"eighty":-6.111623,"marketCap":328340941},{"date":"2026-01-30","current":-5.959837,"twenty":-10.857352,"median":-8.086731,"eighty":-6.108052,"marketCap":290673181},{"date":"2026-02-05","current":-5.607158,"twenty":-10.796303,"median":-8.045838,"eighty":-6.041207,"marketCap":273472296}],"updateTime":1770416494612},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AARD\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2606714847","title":"B. Riley Initiates Aardvark Therapeutics at Buy With $32 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2606714847","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606714847?lang=en_us&edition=fundamental","pubTime":"2026-01-28 21:35","pubTimestamp":1769607325,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics (AARD) has an average rating of buy and mean price target of $32.64, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AARD"],"gpt_icon":0},{"id":"2606197897","title":"Aardvark Therapeutics Inc : B. Riley Initiates Coverage With Buy Rating; Target Price $32","url":"https://stock-news.laohu8.com/highlight/detail?id=2606197897","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606197897?lang=en_us&edition=fundamental","pubTime":"2026-01-28 21:03","pubTimestamp":1769605413,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nFWN3YT0RD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD"],"gpt_icon":0},{"id":"2606792298","title":"Aardvark Therapeutics initiated with a Buy at B. Riley","url":"https://stock-news.laohu8.com/highlight/detail?id=2606792298","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606792298?lang=en_us&edition=fundamental","pubTime":"2026-01-28 17:55","pubTimestamp":1769594110,"startTime":"0","endTime":"0","summary":"B. Riley analyst William Wood initiated coverage of Aardvark Therapeutics (AARD) with a Buy rating and $32 price target The company is developing A...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-initiated-with-a-buy-at-b-riley-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-initiated-with-a-buy-at-b-riley-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AARD"],"gpt_icon":0},{"id":"2605849457","title":"Ten new option listings and two option delistings on January 22nd","url":"https://stock-news.laohu8.com/highlight/detail?id=2605849457","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605849457?lang=en_us&edition=fundamental","pubTime":"2026-01-22 21:36","pubTimestamp":1769088965,"startTime":"0","endTime":"0","summary":"New option listings for January 22nd include Aardvark Therapeutics Inc (AARD), Anteris Technologies Global Corp (AVR), Climb Bio Inc (CLYM), REX Dr...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ten-new-option-listings-and-two-option-delistings-on-january-22nd-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ten-new-option-listings-and-two-option-delistings-on-january-22nd-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AVR","BK4082","BK4539","CLYM","AARD"],"gpt_icon":0},{"id":"2604191017","title":"Aardvark Therapeutics: Clinical Momentum and 2026 Catalyst Stack Underpin Buy Rating and $26 Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2604191017","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604191017?lang=en_us&edition=fundamental","pubTime":"2026-01-20 18:39","pubTimestamp":1768905557,"startTime":"0","endTime":"0","summary":"Analyst Jeet Mukherjee of BTIG reiterated a Buy rating on Aardvark Therapeutics, Inc., retaining the price target of $26.00. Jeet Mukherjee has giv...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/aardvark-therapeutics-clinical-momentum-and-2026-catalyst-stack-underpin-buy-rating-and-26-target-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/aardvark-therapeutics-clinical-momentum-and-2026-catalyst-stack-underpin-buy-rating-and-26-target-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AARD"],"gpt_icon":0},{"id":"2593418632","title":"Aardvark Therapeutics Inc : Oppenheimer Initiates Coverage With Outperform Rating; Target Price $35","url":"https://stock-news.laohu8.com/highlight/detail?id=2593418632","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593418632?lang=en_us&edition=fundamental","pubTime":"2025-12-23 21:20","pubTimestamp":1766496001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nFWN3XT0KP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD"],"gpt_icon":0},{"id":"2593497970","title":"BUZZ-Oppenheimer starts Aardvark with 'outperform' on differentiated obesity franchise","url":"https://stock-news.laohu8.com/highlight/detail?id=2593497970","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593497970?lang=en_us&edition=fundamental","pubTime":"2025-12-23 20:25","pubTimestamp":1766492737,"startTime":"0","endTime":"0","summary":"BUZZ-Oppenheimer starts Aardvarkwith 'outperform' on differentiated obesity franchise** Brokerage Oppenheimer initiates coverage on Aardvark Therapeutics AARD.O with an \"outperform\" rating and a $35 P","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nL6N3XT0JS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","BK4139","SLNO"],"gpt_icon":0},{"id":"2591804638","title":"Aardvark Therapeutics CEO Tien-Li Lee Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2591804638","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591804638?lang=en_us&edition=fundamental","pubTime":"2025-12-13 09:30","pubTimestamp":1765589442,"startTime":"0","endTime":"0","summary":"Tien-Li Lee, Chief Executive Officer and Director of Aardvark Therapeutics Inc., reported the acquisition of common shares of the company, according to a recent SEC filing. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 12, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251213:nNDLbRv6nH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Aardvark Therapeutics CEO Tien-Li Lee Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2591686624","title":"Aardvark's Hunger Suppressing Drug Candidate Could Potentially Address Massive $10 Billion Market: Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2591686624","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591686624?lang=en_us&edition=fundamental","pubTime":"2025-12-13 03:04","pubTimestamp":1765566240,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics gains an Outperform rating as its Phase 3 PWS trial progresses and analysts point to large market potential for ARD-101 and ARD-201.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/12/Diet-And-Dieting--Beauty-Slim-Female-Bod.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/12/Diet-And-Dieting--Beauty-Slim-Female-Bod.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/initiation/25/12/49371535/aardvarks-hunger-suppressing-drug-candidate-could-potentially-address-massive-10-billion-market-analyst","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/initiation/25/12/49371535/aardvarks-hunger-suppressing-drug-candidate-could-potentially-address-massive-10-billion-market-analyst","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["PWS","AARD"],"gpt_icon":0},{"id":"2591141688","title":"Aardvark Therapeutics Initiated at Outperform by William Blair","url":"https://stock-news.laohu8.com/highlight/detail?id=2591141688","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591141688?lang=en_us&edition=fundamental","pubTime":"2025-12-13 00:37","pubTimestamp":1765557420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AARD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 12, 2025 11:37 ET (16:37 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2590091405","title":"William Blair Initiates Aardvark Therapeutics With Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2590091405","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590091405?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:05","pubTimestamp":1765544745,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics, Inc. (AARD) has an average rating of Buy and mean price target of $33.38, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AARD"],"gpt_icon":0},{"id":"2590558148","title":"Aardvark Therapeutics Doses First Patient in Phase 3 HERO Trial for Prader-Willi Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2590558148","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590558148?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:05","pubTimestamp":1765400712,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics Inc. has announced the dosing of the first patient in Australia as part of its Phase 3 HERO pivotal clinical trial evaluating ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi syndrome . Regulatory clearance for trial enrollment has also been received in Canada and the United Kingdom, with enrollment already underway in the United States and Australia. The company reports strong interest and participation from the patient community, noting that all patients who have completed the 12-week trial to date have enrolled in the Open Label Extension trial. Aardvark anticipates topline data from the HERO trial will be available in Q3 2026. No results have been presented yet.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, inves","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL1jtNCN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","BK4585","LU2095319765.USD","LU2210150020.SGD","LU0314104364.USD","BK4588","SG9999014005.SGD","LU2210149790.SGD","IE00BKPKM429.USD","SG9999014013.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014039.USD","BK4112","IE00BGHQF748.EUR","AARD","SG9999014021.USD"],"gpt_icon":0},{"id":"2590558673","title":"Aardvark Therapeutics Announces First Patient Dosed in Australia in Hero Phase 3 Trial for Prader-Willi Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2590558673","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590558673?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:05","pubTimestamp":1765400700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUA7G2YTX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD"],"gpt_icon":0},{"id":"2590553397","title":"Aardvark Therapeutics Inc - Regulatory Clearance for Enrollment by Clinical Trial Sites in Canada and the UK Has Also Been Received","url":"https://stock-news.laohu8.com/highlight/detail?id=2590553397","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590553397?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:05","pubTimestamp":1765400700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUA7G2YTX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD"],"gpt_icon":0},{"id":"2588104536","title":"Raymond James Initiates Aardvark Therapeutics at Strong Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2588104536","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588104536?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:12","pubTimestamp":1764763966,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics (AARD) has an average rating of buy and mean price target of $32.44, according to analysts polled by FactSet. Price Target(MT Newswires covers equity, commodity and economic rese","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B64PRP62.GBP","LU0971096721.USD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","BK4127","AARD","BK4585","LU1363072403.SGD","BK4588","RJF","LU1804176565.USD","LU2265009873.SGD"],"gpt_icon":0},{"id":"2586409805","title":"Aardvark Therapeutics to Present at Upcoming Healthcare Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2586409805","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586409805?lang=en_us&edition=fundamental","pubTime":"2025-11-26 05:05","pubTimestamp":1764104726,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics Inc. will present at the Piper Sandler 37th Annual Healthcare Conference in New York on Wednesday, December 3 at 8:00 a.m. ET, and at the Evercore ISI 8th Annual Healthcare Conference in Miami on Thursday, December 4 at 11:15 a.m. ET. Live webcasts of each presentation will be available on the company's website under the investors section.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on November 25, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL1Hpzy5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","IE00BGHQF748.EUR","PIPR","NDAQ","BK4127","BK4585","EVR","IE00B64PRP62.GBP","LU2095319765.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","LU0314104364.USD","AARD","BK4588","LU2210149790.SGD"],"gpt_icon":0},{"id":"2584009576","title":"Aardvark Therapeutics Reports Q3 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2584009576","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584009576?lang=en_us&edition=fundamental","pubTime":"2025-11-18 12:07","pubTimestamp":1763438855,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics, Inc. ( ($AARD) ) has released its Q3 earnings. Here is a breakdown of the information Aardvark Therapeutics, Inc. presented ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aardvark-therapeutics-reports-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aardvark-therapeutics-reports-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AARD"],"gpt_icon":0},{"id":"2583150015","title":"Aardvark Therapeutics Is Maintained at Outperform by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2583150015","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583150015?lang=en_us&edition=fundamental","pubTime":"2025-11-14 23:47","pubTimestamp":1763135220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AARD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 14, 2025 10:47 ET (15:47 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2583509025","title":"Cantor Fitzgerald Reaffirms Their Buy Rating on Aardvark Therapeutics, Inc. (AARD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583509025","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583509025?lang=en_us&edition=fundamental","pubTime":"2025-11-14 21:36","pubTimestamp":1763127381,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald analyst Joshua Schimmer reiterated a Buy rating on Aardvark Therapeutics, Inc. yesterday and set a price target of $50.00. The co...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-reaffirms-their-buy-rating-on-aardvark-therapeutics-inc-aard-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-reaffirms-their-buy-rating-on-aardvark-therapeutics-inc-aard-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AARD"],"gpt_icon":0},{"id":"2583054635","title":"BTIG Remains a Buy on Aardvark Therapeutics, Inc. (AARD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583054635","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583054635?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:35","pubTimestamp":1763123739,"startTime":"0","endTime":"0","summary":"BTIG analyst Jeet Mukherjee reiterated a Buy rating on Aardvark Therapeutics, Inc. today and set a price target of $26.00. Mukherjee covers the Hea...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/btig-remains-a-buy-on-aardvark-therapeutics-inc-aard-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/btig-remains-a-buy-on-aardvark-therapeutics-inc-aard-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AARD"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":66,"code":"91000000","status":"200"}]}}